These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4879540)

  • 41. [Experiences in the demonstration of dyspepsia coli bacteria by means of fluorescent antiserums].
    Bösenberg H
    Arch Hyg Bakteriol; 1968 Dec; 152(5):453-6. PubMed ID: 4907117
    [No Abstract]   [Full Text] [Related]  

  • 42. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Update on antibiotic therapy. 17) A combination of fosfomycin and cephalexin (cefemic cofosfolactamine)].
    Di Nola F
    Minerva Med; 1983 May; 74(20):1217-22. PubMed ID: 6379514
    [No Abstract]   [Full Text] [Related]  

  • 44. [Immunofluorescence of enteropathogenic E. coli following antibiotic treatment].
    Raue W; Kühn B
    Kinderarztl Prax; 1967 Dec; 35(12):539-41. PubMed ID: 4884501
    [No Abstract]   [Full Text] [Related]  

  • 45. Treatment of bacterial infections of the central nervous system.
    Bell WE
    Ann Neurol; 1981 Apr; 9(4):313-27. PubMed ID: 7013653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence for transmission of Escherichia coli from mother to child in late-onset neonatal infection.
    Raymond J; Lopez E; Bonacorsi S; Poyart C; Moriette G; Jarreau PH; Bingen E
    Pediatr Infect Dis J; 2008 Feb; 27(2):186-8. PubMed ID: 18174860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The therapeutic effect of chloronitrin in dyspepsia coli].
    HOFFMANN HU; BEIERSDORF R
    Dtsch Gesundheitsw; 1955 Sep; 10(37):1220-1. PubMed ID: 13261660
    [No Abstract]   [Full Text] [Related]  

  • 48. The role of treatment with proton pump inhibitors and anti-Helicobacter therapy in functional dyspepsia.
    Veldhuyzen van Zanten SJ
    Am J Gastroenterol; 2001 Oct; 96(10):2811-2. PubMed ID: 11693312
    [No Abstract]   [Full Text] [Related]  

  • 49. [Urinary tract infections in Ain M'lila (Algeria). Antibiotic resistance of 239 strains isolated between 2006 and 2007].
    Bouzenoune F; Boudersa F; Bensaad A; Harkat F; Siad N
    Med Mal Infect; 2009 Feb; 39(2):142-3. PubMed ID: 19118964
    [No Abstract]   [Full Text] [Related]  

  • 50. [COLI DYSPEPSIA].
    OCKLITZ HW
    Dtsch Med Wochenschr; 1965 Jan; 90():214-9. PubMed ID: 14240840
    [No Abstract]   [Full Text] [Related]  

  • 51. Antimicrobial therapy and shedding time of Shiga toxin-producing Escherichia coli.
    Ichinohe S; Ichinohe N; Sakuma F
    Scand J Infect Dis; 2008; 40(11-12):1002-3. PubMed ID: 18720258
    [No Abstract]   [Full Text] [Related]  

  • 52. [The use of fluorescent antibodies in the study of various infectious diseases. IV. Results obtained using the fluorescent antibody technic and the culture of enteropathogenic infections by Escherichia coli].
    Olarte J; Ramos Alvarez M; Galindo E
    Gac Med Mex; 1964 Apr; 94(4):319-24. PubMed ID: 4891439
    [No Abstract]   [Full Text] [Related]  

  • 53. [Clinico-therapeutic considerations on a recent series of cases of bacterial purulent meningitis in childhood].
    Rosaschino F; Flauto U
    G Mal Infett Parassit; 1968 May; 20(5):464-8. PubMed ID: 4909031
    [No Abstract]   [Full Text] [Related]  

  • 54. Successful clearance of catheter-related bloodstream infection by antibiotic lock therapy using ampicillin.
    Elwood RL; Spencer SE
    Ann Pharmacother; 2006 Feb; 40(2):347-50. PubMed ID: 16449537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis.
    Paterson DL; Singh N; Gayowski T; Marino IR
    Clin Infect Dis; 1999 Mar; 28(3):683-4. PubMed ID: 10194100
    [No Abstract]   [Full Text] [Related]  

  • 56. [The discovery of a natural phenomenon, "Phage-Antibiotic Synergy". Implications for phage therapy].
    Comeau AM; Tétart F; Trojet SN; Prère MF; Krisch HM
    Med Sci (Paris); 2008 May; 24(5):449-51. PubMed ID: 18466714
    [No Abstract]   [Full Text] [Related]  

  • 57. Helicobacter pylori and nonulcer dyspepsia.
    Püspök A; Oberhuber G
    N Engl J Med; 1999 May; 340(19):1508-9; author reply 1509-11. PubMed ID: 10328716
    [No Abstract]   [Full Text] [Related]  

  • 58. [Fluorescence serological demonstration of coli dyspepsia in routine operation. Problems of economy and technique].
    Gebert P
    Z Arztl Fortbild (Jena); 1965 Feb; 59(3):146-51. PubMed ID: 4161198
    [No Abstract]   [Full Text] [Related]  

  • 59. [Observations on infant dyspepsia].
    VEGHELYI P; VINCE I; REVESZ K; SZEKELY A; BENDZSEL R; FURESZ I; KUBINYI J
    Gyermekgyogyaszat; 1953 Apr; 4(4):97-104. PubMed ID: 13060762
    [No Abstract]   [Full Text] [Related]  

  • 60. [IMMUNE FLUORESCENT TESTS AND THEIR SIGNIFICANCE IN THE CONTROL OF DYSPEPSIA COLI].
    GECK P; GAGO G; KOVACS S
    Orv Hetil; 1965 Jun; 106():1171-2. PubMed ID: 14334379
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.